collection
Collections Most Read Papers - Endocrinolo...

Most Read Papers - Endocrinology, Metabolism

https://read.qxmd.com/read/38569055/association-between-treatment-adherence-and-continuous-glucose-monitoring-outcomes-in-people-with-diabetes-using-smart-insulin-pens-in-a-real-world-setting
#1
JOURNAL ARTICLE
Thomas Danne, Michael Joubert, Niels Væver Hartvig, Anne Kaas, Nikoline Nygård Knudsen, Julia K Mader
OBJECTIVE: To evaluate the association of insulin injection adherence, smart insulin pen engagement, and glycemic control using real-world data from 16 countries from adults self-administering basal insulin degludec and bolus insulin with a smart insulin pen (NovoPen 6 or NovoPen Echo Plus) alongside continuous glucose monitoring (CGM). RESEARCH DESIGN AND METHODS: Data were aggregated over 14-day periods. Treatment adherence was defined according to the number of missed basal and missed bolus insulin doses and smart pen engagement according to the number of days with data uploads...
April 3, 2024: Diabetes Care
https://read.qxmd.com/read/38527759/effectiveness-and-safety-of-drugs-for-obesity
#2
REVIEW
Kristina Henderson, Lewis, Caroline E Sloan, Daniel H Bessesen, David Arterburn
Recent publicity around the use of new antiobesity medications (AOMs) has focused the attention of patients and healthcare providers on the role of pharmacotherapy in the treatment of obesity. Newer drug treatments have shown greater efficacy and safety compared with older drug treatments, yet access to these drug treatments is limited by providers' discomfort in prescribing, bias, and stigma around obesity, as well as by the lack of insurance coverage. Now more than ever, healthcare providers must be able to discuss the risks and benefits of the full range of antiobesity medications available to patients, and to incorporate both guideline based advice and emerging real world clinical evidence into daily clinical practice...
March 25, 2024: BMJ: British Medical Journal
https://read.qxmd.com/read/38572616/impact-of-insulin-sensitization-on-metabolic-and-fertility-outcomes-in-women-with-polycystic-ovary-syndrome-and-overweight-or-obesity-a-systematic-review-meta-analysis-and-meta-regression
#3
REVIEW
Suhaniya N S Samarasinghe, Eduard Ostarijas, Matthew J Long, Simon Erridge, Sanjay Purkayastha, Georgios K Dimitriadis, Alexander D Miras
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. This systematic review, meta-analysis, and meta-regression aims to compare the effect of insulin sensitizer pharmacotherapy on metabolic and reproductive outcomes in women with PCOS and overweight or obesity. We searched online databases MEDLINE via OVID, EMBASE, Clinicaltrials.gov, and EudraCT for trials published from inception to November 13, 2023. Inclusion criteria were double-blind, randomized controlled trials in women diagnosed with PCOS, body mass index (BMI) ≥ 25 kg/m2 , which reported metabolic or reproductive outcomes...
April 4, 2024: Obesity Reviews
https://read.qxmd.com/read/38534014/macroprolactin-over-time-is-there-any-point-in-rechecking-it-in-people-with-a-persistently-elevated-serum-prolactin
#4
JOURNAL ARTICLE
Mark Livingston, Syeda F Hashmi, Sudarshan Ramachandran, Ian Laing, Adrian Heald
OBJECTIVE AND DESIGN: Macroprolactinemia may influence the interpretation of serum prolactin levels-a recognised phenomenon since 1981. The degree of macroprolactinaemia over time is less well described. We determined how macroprolactin status (based on polyethylene glycol (PEG) precipitation) varied by analysing serial measurements in hyperprolactinaemic individuals over a period of 9 years. PATIENTS AND MEASUREMENTS: Results from 1810 individuals were included...
March 27, 2024: Clinical Endocrinology
https://read.qxmd.com/read/38558280/effect-of-combination-pioglitazone-with-sodium-glucose-cotransporter-2-inhibitors-or-glucagon-like-peptide-1-receptor-agonists-on-outcomes-in-type-2-diabetes-a-systematic-review-meta-analysis-and-real-world-study-from-an-international-federated-database
#5
JOURNAL ARTICLE
Matthew Anson, Alex E Henney, Sizheng S Zhao, Gema H Ibarburu, Gregory Y H Lip, Daniel J Cuthbertson, Katarzyna Nabrdalik, Uazman Alam
AIMS: To evaluate the efficacy and cardiovascular outcomes of combination pioglitazone with either a glucagon-like peptide-1 receptor agonist (GLP-1RA) or a sodium-glucose cotransporter-2 (SGLT2) inhibitor in individuals with type 2 diabetes (T2D) by conducting a systematic review, meta-analysis, and analysis of a large international real-world database. METHODS: We searched MEDLINE, SCOPUS and Web of Science to identify relevant articles for inclusion (PROSPERO [CRD: 42023483126])...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38497438/adverse-effects-of-aldosterone-beyond-blood-pressure
#6
REVIEW
Jenifer M Brown
Aldosterone is a steroid hormone that primarily acts through activation of the mineralocorticoid receptor (MR), a nuclear receptor responsible for downstream genomic regulation. Classically, activation of the MR in the renal tubular epithelium is responsible for sodium retention and volume expansion, raising systemic blood pressure. However, activation of the MR across a wide distribution of tissue types has been implicated in multiple adverse consequences for cardiovascular, cerebrovascular, renal, and metabolic disease, independent of blood pressure alone...
March 18, 2024: Journal of the American Heart Association
https://read.qxmd.com/read/38552140/point-of-care-hba1c-in-clinical-practice-caveats-and-considerations-for-optimal-use
#7
REVIEW
David B Sacks, M Sue Kirkman, Randie R Little
Hemoglobin A1c (A1C) is widely used for the diagnosis and management of diabetes. Accurate measurement of A1C is necessary for optimal clinical value. Assay standardization has markedly improved the accuracy and consistency of A1C testing. Devices to measure A1C at point of care (POC) are commercially available, allowing rapid results when the patient is seen. In this review, we describe how standardization of A1C testing was achieved, leading to high-quality results in clinical laboratories. We address the use of POC A1C testing in clinical situations and summarize the advantages and disadvantages of POC A1C testing...
March 29, 2024: Diabetes Care
https://read.qxmd.com/read/29074724/conversion-of-prps-hexamer-to-monomer-by-ampk-mediated-phosphorylation-inhibits-nucleotide-synthesis-in-response-to-energy-stress
#8
JOURNAL ARTICLE
Xu Qian, Xinjian Li, Lin Tan, Jong-Ho Lee, Yan Xia, Qingsong Cai, Yanhua Zheng, Hongxia Wang, Philip L Lorenzi, Zhimin Lu
Tumors override energy stress to grow. However, how nucleotide synthesis is regulated under energy stress is unclear. We demonstrate here that glucose deprivation or hypoxia results in the AMPK-mediated phosphorylation of phosphoribosyl pyrophosphate synthetase 1 (PRPS1) S180 and PRPS2 S183, leading to conversion of PRPS hexamers to monomers and thereby inhibiting PRPS1/2 activity, nucleotide synthesis, and nicotinamide adenine dinucleotide (NAD) production. Knock-in of nonphosphorylatable PRPS1/2 mutants, which have uninhibited activity, in brain tumor cells under energy stress exhausts cellular ATP and NADPH and increases reactive oxygen species levels, thereby promoting cell apoptosis...
January 2018: Cancer Discovery
https://read.qxmd.com/read/38541083/a-review-and-meta-analysis-of-the-safety-and-efficacy-of-using-glucagon-like-peptide-1-receptor-agonists
#9
REVIEW
En-Hao Hu, Ming-Lung Tsai, Yuan Lin, Tien-Shin Chou, Tien-Hsing Chen
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce glucose levels in patients with type 2 diabetes mellitus since 2005. This meta-analysis discusses the mechanisms and potential benefits of several GLP-1 RAs. In particular, this meta-analysis focuses on the safety and associations with weight loss, glucose reduction, cardiovascular outcomes, heart failure, and renal outcomes of GLP-1 RAs to determine their benefits for patients with different conditions. In terms of glycemic control and weight loss, semaglutide was statistically superior to other GLP-1 RAs...
February 21, 2024: Medicina
https://read.qxmd.com/read/38549284/pseudoacromegaly-a-challenging-entity-in-the-endocrine-clinic-a-systematic-review
#10
JOURNAL ARTICLE
Pedro Marques, Inês Sapinho, Márta Korbonits
OBJECTIVE: Pseudoacromegaly encompasses conditions with features of acromegaly/gigantism, but no growth hormone (GH) or insulin-like growth factor-1 (IGF-1) excess. We aimed to review published pseudoacromegaly cases evaluated due to clinical suspicion of acromegaly. DESIGN/PATIENTS: PubMed/Medline search was conducted to identify reported pseudoacromegaly cases, which were systematically reviewed to ensure they met eligibility criteria: (1) presentation suggestive of acromegaly; (2) acromegaly excluded based on normal GH, IGF-1 and/or GH suppression on oral glucose tolerance test (OGTT-GH); (3) diagnosis of the pseudoacromegaly condition was established...
March 28, 2024: Clinical Endocrinology
https://read.qxmd.com/read/38517306/epigenetic-mechanisms-modulated-by-glucocorticoids-with-a-focus-on-cushing-s-syndrome
#11
JOURNAL ARTICLE
Ticiana Paes, Richard A Feelders, Leo J Hofland
In Cushing's syndrome (CS), prolonged exposure to high cortisol levels results in a wide range of devastating effects causing multisystem morbidity. Despite the efficacy of treatment leading to disease remission and clinical improvement, hypercortisolism-induced complications may persist. Since glucocorticoids use the epigenetic machinery as a mechanism of action to modulate gene expression, the persistence of some comorbidities may be mediated by hypercortisolism-induced long-lasting epigenetic changes. Additionally, glucocorticoids influence microRNA expression which is an important epigenetic regulator as it modulates gene expression without changing the DNA sequence...
March 22, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38472620/renal-effects-of-glp-1-receptor-agonists-and-tirzepatide-in-individuals-with-type-2-diabetes-seeds-of-a-promising-future
#12
REVIEW
Irene Caruso, Francesco Giorgino
PURPOSE: Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management. The dual GIP/GLP-1 receptor agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects. This review aims to summarize the evidence regarding the nephroprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) and tirzepatide and the putative mechanisms underlying the favorable renal profile of tirzepatide...
March 12, 2024: Endocrine
https://read.qxmd.com/read/38473732/potential-mechanisms-of-the-protective-effects-of-the-cardiometabolic-drugs-type-2-sodium-glucose-transporter-inhibitors-and-glucagon-like-peptide-1-receptor-agonists-in-heart-failure
#13
REVIEW
Giovanna Gallo, Massimo Volpe
Different multifactorial pathophysiological processes are involved in the development of heart failure (HF), including neurohormonal dysfunction, the hypertrophy of cardiomyocytes, interstitial fibrosis, microvascular endothelial inflammation, pro-thrombotic states, oxidative stress, decreased nitric oxide (NO) bioavailability, energetic dysfunction, epicardial coronary artery lesions, coronary microvascular rarefaction and, finally, cardiac remodeling. While different pharmacological strategies have shown significant cardiovascular benefits in HF with reduced ejection fraction (HFrEF), there is a residual unmet need to fill the gap in terms of knowledge of mechanisms and efficacy in the outcomes of neurohormonal agents in HF with preserved ejection fraction (HFpEF)...
February 20, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38200100/efficacy-and-safety-of-mineralocorticoid-receptor-antagonists-for-the-treatment-of-low-renin-hypertension-a-systematic-review-and-meta-analysis
#14
JOURNAL ARTICLE
Sonali S Shah, Jinghong Zhang, Stella May Gwini, Morag J Young, Peter J Fuller, Jun Yang
Hypertension is the leading risk factor for premature death. The optimal treatment of low-renin hypertension (LRH), present in 30% of hypertensive individuals, is not known. LRH likely reflects a state of excess salt, expanded volume and/or mineralocorticoid receptor (MR) activation. Therefore, targeted treatment with MR antagonists (MRA) may be beneficial. The objective of this systematic review was to assess the efficacy of MRA therapy in LRH. MEDLINE, Embase and Cochrane databases were searched for randomised controlled trials of adults with LRH that compared the efficacy of MRA to placebo or other antihypertensive treatments...
January 11, 2024: Journal of Human Hypertension
https://read.qxmd.com/read/38526760/obesity-and-obesity-related-thyroid-dysfunction-any-potential-role-for-the-very-low-calorie-ketogenic-diet-vlckd
#15
REVIEW
Sebastián Pablo Chapela, Alison Simancas-Racines, Florencia Ceriani, Andrés Luciano Nicolas Martinuzzi, María Paula Russo, Ana Karina Zambrano, Daniel Simancas-Racines, Ludovica Verde, Giovanna Muscogiuri, Christos S Katsanos, Evelyn Frias-Toral, Luigi Barrea
PURPOSE OF REVIEW: This review aims to explore in-depth the different aspects of the association between very low-calorie ketogenic diet (VLCKD), obesity and obesity-related thyroid dysfunction. RECENT FINDINGS: The VLCKD, proposed as a non-pharmacological strategy for the management of certain chronic diseases, is becoming increasingly popular worldwide. Initially used to treat epilepsy, it has been shown to be effective in controlling body weight gain and addressing various pathophysiological conditions...
March 25, 2024: Current Nutrition Reports
https://read.qxmd.com/read/38500154/effectiveness-and-safety-of-the-combination-of-sodium-glucose-transport-protein-2-inhibitors-and-glucagon-like-peptide-1-receptor-agonists-in-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-of-observational-studies
#16
JOURNAL ARTICLE
Aftab Ahmad, Hani Sabbour
BACKGROUND: Randomized controlled trials and real-world studies suggest that combination therapy with sodium-glucose transport protein 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with improvement in fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), systolic blood pressure (SBP), body mass index (BMI), and total cholesterol levels. However, a systematic review of available real-world evidence may facilitate clinical decision-making in the real-world scenario...
March 18, 2024: Cardiovascular Diabetology
https://read.qxmd.com/read/38478374/approach-to-the-patient-with-bilateral-adrenal-masses
#17
JOURNAL ARTICLE
Dimitra-Argyro Vassiliadi, Danae-Anastasia Delivanis, Olga Papalou, Stylianos Tsagarakis
Bilateral adrenal masses, increasingly encountered in clinical practice, manifest across diverse contexts, including incidental discovery, malignancy staging, and targeted imaging after hormonal diagnosis of adrenal disorders. The spectrum encompasses various pathologies, such as cortical adenomas, macronodular adrenal disease, pheochromocytomas, myelolipomas, infiltrative disorders, primary and secondary malignancies. Notably, not all masses in both adrenal glands necessarily share the same etiology, often exhibiting diverse causes...
March 13, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38502868/a-delicate-balance-the-challenges-of-hypoparathyroidism
#18
JOURNAL ARTICLE
Garyfallia Papaioannou, Michael Mannstadt
A 38-year-old woman with chronic non-surgical hypoparathyroidism, managed elsewhere, presented to our practice with symptomatic hypocalcemia. At the age of 17, she began to suffer from muscle cramps, paresthesia, and ongoing diffuse pain. It took years before she was correctly diagnosed with hypoparathyroidism. Her symptoms were severe enough that she required emergency room (ER) visits several times a year. After she was properly diagnosed and started on calcium and calcitriol therapy, she continued to experience frequent episodes of severe hypocalcemia...
March 19, 2024: Journal of Bone and Mineral Research
https://read.qxmd.com/read/38500373/targeting-cell-senescence-and-senolytics-novel-interventions-for-age-related-endocrine-dysfunction
#19
JOURNAL ARTICLE
Masayoshi Suda, Karl H Paul, Utkarsh Tripathi, Tohru Minamino, Tamara Tchkonia, James L Kirkland
Multiple changes occur in hormonal regulation with aging and across various endocrine organs. These changes are associated with multiple age-related disorders and diseases. A better understanding of responsible underling biological mechanisms could help in the management of multiple endocrine disorders over and above hormone replacement therapy (HRT). Cellular senescence is involved in multiple biological aging processes and pathologies common in elderly individuals. Cellular senescence, which occurs in many older individuals but also across the lifespan in association with tissue damage, acute and chronic diseases, certain drugs, and genetic syndromes, may contribute to such endocrine disorders as osteoporosis, metabolic syndrome, and type II diabetes mellitus (T2DM)...
March 19, 2024: Endocrine Reviews
https://read.qxmd.com/read/38488566/relative-energy-deficiency-in-sport-reds-endocrine-manifestations-pathophysiology-and-treatments
#20
JOURNAL ARTICLE
Angeliki M Angelidi, Konstantinos Stefanakis, Sharon H Chou, Laura Valenzuela-Vallejo, Konstantina Dipla, Chrysoula Boutari, Konstantinos Ntoskas, Panagiotis Tokmakidis, Alexander Kokkinos, Dimitrios G Goulis, Helen A Papadaki, Christos S Mantzoros
Research on lean, energy-deficient athletic and military cohorts has broadened the concept of the Female Athlete Triad into the Relative Energy Deficiency in Sport (REDs) syndrome. REDs represents a spectrum of abnormalities induced by low energy availability (LEA), which serves as the underlying cause of all symptoms described within the REDs concept, affecting exercising populations of either biological sex. Both short- and long-term LEA, in conjunction with other moderating factors, may produce a multitude of maladaptive changes that impair various physiological systems and adversely affect health, well-being, and sport performance...
March 15, 2024: Endocrine Reviews
label_collection
label_collection
1045
1
2
2024-03-26 00:25:03
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.